October 9, 2023 10:55 AM EDTUpdated 11:10 AM

BridgeBio’s long-term limb-girdle muscular dystrophy data; QHP buys a CDMO

Lei Lei Wu

News Reporter

Jaimy Lee

Deputy Editor

BridgeBio shares longer-term PhII data in limb-girdle: BridgeBio said that patients with limb-girdle muscular dystrophy type 2I/R9 treated with BBP-418 saw …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BridgeBio’s long-term limb-girdle muscular dystrophy data; QHP buys a CDMO

Lei Lei Wu

News Reporter

Jaimy Lee

Deputy Editor

Sign up to read this article for free.

Gardasil demand in China sinks, and Merck expects the same next quarter

‘Imitation is best form of flattery’: Regeneron CEO comments on Amgen’s Eylea biosimilar

UCB's anti-tau Alzheimer's program fails Phase 2 primary endpoint, but highlights positive secondaries

Amgen makes pipeline cuts, but obesity plans remain the focus

AbbVie adds to T cell engager momentum, with EvolveImmune pact starting at $65M

Q&A: Jade CEO talks about reverse merger and IgAN drugs

Bridge­Bio’s long-term limb-gir­dle mus­cu­lar dy­s­tro­phy da­ta; QHP buys a CD­MO

News Reporter

Deputy Editor

Sign up to read this article for free.

more like this

BridgeBio’s long-term limb-girdle muscular dystrophy data; QHP buys a CDMO